What is the standard diagnostic workup, staging, and first‑line treatment—including induction, autologous stem‑cell transplantation, consolidation, maintenance, and supportive care—for a newly diagnosed multiple myeloma patient, and how does the approach differ for transplant‑eligible versus transplant‑ineligible individuals?

Multiple Myeloma: Diagnostic Workup, Staging, and First-Line Treatment

Diagnostic Workup

All patients require serum protein electrophoresis (SPEP) with immunofixation, 24-hour urine protein electrophoresis (UPEP) with immunofixation, serum free light chain assay, complete blood count, comprehensive metabolic panel including calcium and creatinine, LDH, β2-microglobulin, albumin, bone marrow aspiration/biopsy with FISH cytogenetics, and whole-body imaging with CT, PET-CT, or MRI. 1, 2, 3

Laboratory Assessment

• Serum studies: Quantitative immunoglobulins (IgG, IgA, IgM), SPEP, serum immunofixation, and serum free light chain ratio are essential for detecting and quantifying M-protein 1, 2
• Urine studies: 24-hour urine collection for total protein, UPEP, and urine immunofixation to detect light chain excretion 1, 2
• Baseline blood work: CBC with differential, BUN, creatinine, electrolytes, calcium, albumin, LDH, and β2-microglobulin to assess organ function and tumor burden 1, 2

Bone Marrow and Cytogenetics

• Bone marrow biopsy is mandatory to quantify plasma cell infiltration (≥10% clonal plasma cells required for diagnosis) 2, 3
• FISH cytogenetic analysis must identify high-risk features including del(17p), t(4;14), t(14;16), t(14;20), gain 1q, del 1p, or p53 mutation 2, 3
• Patients with ≥2 high-risk factors have "double-hit" myeloma; ≥3 factors constitute "triple-hit" myeloma with significantly worse prognosis 3, 4

Imaging

• Whole-body imaging with CT, PET-CT, or MRI (not plain radiographs) is required to detect lytic lesions, focal lesions, and extramedullary disease 2, 3

Staging and Risk Stratification

Use the Revised International Staging System (R-ISS) combining β2-microglobulin, albumin, LDH, and high-risk cytogenetics to stratify patients into three prognostic groups. 2, 3

R-ISS Classification

• Stage I: β2-microglobulin <3.5 mg/L, albumin ≥3.5 g/dL, normal LDH, no high-risk cytogenetics (median 5-year survival 82%) 2, 5
• Stage II: Not Stage I or III 2
• Stage III: β2-microglobulin >5.5 mg/L or high-risk cytogenetics or elevated LDH (poorest prognosis) 2, 3

Diagnostic Criteria (CRAB + MDE)

• Symptomatic myeloma requires ≥10% clonal bone marrow plasma cells PLUS one or more myeloma-defining events 3, 4:
  • CRAB criteria: Hypercalcemia (>11 mg/dL), Renal insufficiency (creatinine >2 mg/dL), Anemia (hemoglobin <10 g/dL or 2 g/dL below normal), Bone lesions (lytic lesions or pathologic fractures) 1, 2, 3
  • Additional MDE: Bone marrow plasma cells ≥60%, serum involved/uninvolved FLC ratio ≥100 (with involved FLC ≥100 mg/L), or >1 focal lesion on MRI 3, 4

Treatment Approach: Transplant-Eligible Patients

For transplant-eligible patients (typically age <65-70 years with good performance status and minimal comorbidities), administer 3-4 cycles of quadruplet induction therapy with daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRd), followed by autologous stem cell transplantation with melphalan 200 mg/m², then lenalidomide maintenance (with bortezomib added for high-risk disease). 2, 3, 4

Induction Therapy

• Standard-risk patients: Bortezomib-lenalidomide-dexamethasone (VRd) for 3-4 cycles achieves median progression-free survival of 41 months 2, 4, 5
• High-risk patients: Daratumumab-VRd (Dara-VRd) is preferred over VRd alone to improve outcomes in patients with high-risk cytogenetics 3, 4
• Alternative triplet regimens include VTD (bortezomib-thalidomide-dexamethasone), VCD (bortezomib-cyclophosphamide-dexamethasone), or PAD (bortezomib-doxorubicin-dexamethasone), though these are less commonly used now 1, 2

Critical pitfall: Avoid melphalan or other alkylating agents during induction as they damage stem cells and compromise harvest 1

Stem Cell Collection and Transplantation

• Peripheral blood progenitor cells (not bone marrow) should be collected after induction, typically using G-CSF mobilization 1
• High-dose melphalan 200 mg/m² IV is the standard conditioning regimen before autologous stem cell transplantation 1, 2, 5
• Timing: Selected standard-risk patients may delay transplant until first relapse after collecting stem cells, but high-risk patients should proceed immediately 3, 4

Consolidation and Maintenance

• Lenalidomide maintenance is standard for all transplanted patients to prolong progression-free survival and possibly overall survival 2, 5
• High-risk patients require bortezomib plus lenalidomide maintenance (not lenalidomide alone) to address aggressive disease biology 3, 4
• Duration: Maintenance continues until disease progression or intolerable toxicity 2, 3

Treatment Approach: Transplant-Ineligible Patients

For transplant-ineligible patients (typically age ≥70 years, poor performance status, or significant comorbidities), treat with continuous triplet therapy using either VRd for 8-12 cycles followed by lenalidomide maintenance, or daratumumab-lenalidomide-dexamethasone (DRd) until progression. 2, 3, 4

First-Line Regimens

• VRd (8-12 cycles) followed by lenalidomide maintenance is a standard option providing finite therapy duration 3, 4
• DRd (daratumumab-lenalidomide-dexamethasone) until progression is an alternative continuous therapy approach 3, 4
• VMP (bortezomib-melphalan-prednisone): Bortezomib 1.3 mg/m² subcutaneously days 1,8,15,22; melphalan 9 mg/m² orally days 1-4; prednisone 60 mg/m² orally days 1-4; repeated every 35 days 1, 2
• MPT (melphalan-prednisone-thalidomide) is an older regimen now largely replaced by novel agent combinations 1

Important consideration: Lenalidomide-dexamethasone (Rd) is widely used in the United States but was not approved in Europe at the time of earlier guidelines; it remains highly effective 1, 2

Supportive Care

All patients with stage III or active bone disease require long-term bisphosphonate therapy (zoledronic acid or pamidronate) or denosumab to reduce skeletal-related events, pathologic fractures, and bone pain. 1, 2, 6

Bone-Protective Therapy

• Bisphosphonates (oral or intravenous) reduce skeletal events and should be administered long-term 1, 2
• Timing interruption: Discontinue bone-modifying agents during stem cell harvest, conditioning, and 3-6 months post-transplant to allow engraftment and immune reconstitution 7
• Restart criteria: Resume bone-protective therapy 3-6 months post-transplant once hematopoietic engraftment is confirmed, immune reconstitution has begun, no active infections are present, and renal function is stable 7

Tumor Lysis Syndrome Prophylaxis

• High-risk patients (high tumor burden, renal insufficiency at diagnosis [~30% of patients], elevated LDH) require aggressive IV hydration with normal saline at 150-200 mL/hour to achieve urine output >100 mL/hour 2, 7
• Rasburicase 0.2 mg/kg IV as a single dose (or 3-6 mg fixed dose) rapidly reduces uric acid levels before initiating chemotherapy 2

Critical pitfall: Do not delay effective bortezomib-based chemotherapy for extended periods while attempting conservative measures alone in patients with renal involvement, as this worsens outcomes 2

Additional Supportive Measures

• Renal protection: Maintain hydration, avoid nephrotoxic agents, and consider dose adjustments for renally cleared drugs 1, 2
• Infection prophylaxis: Consider antimicrobial prophylaxis during intensive therapy, as infection rates are high (26 infections including 14 pulmonary infections within 90 days in transplant patients) 7
• Anemia management: Erythropoiesis-stimulating agents or transfusions as needed 1

Response Monitoring

Check M-protein (serum/urine electrophoresis) and serum free light chains after 1-2 cycles initially to ensure no progression, then every other cycle during active treatment. 2

Response Criteria

• Stringent complete response (sCR): CR plus normal FLC ratio and absence of clonal plasma cells by immunohistochemistry 2
• Complete response (CR): Negative immunofixation in serum and urine, <5% plasma cells in bone marrow 1, 2
• Very good partial response (VGPR): ≥90% reduction in M-protein 2
• Partial response (PR): ≥50% reduction in serum M-protein and ≥90% reduction in 24-hour urine M-protein 1, 2

Smoldering (Asymptomatic) Myeloma

Patients with smoldering myeloma (≥10% bone marrow plasma cells or M-protein ≥3 g/dL WITHOUT CRAB criteria or other myeloma-defining events) should be observed without immediate treatment, with monitoring every 3-6 months using laboratory tests and clinical assessment. 1, 2

This observation approach is critical because immediate treatment does not improve outcomes in asymptomatic patients, and delaying therapy until symptomatic disease develops allows patients to avoid treatment-related toxicity 1